TrialInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study.

Shashi Bhushan B L et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.